Phase II trial of veliparib and temozolomide in metastatic breast cancer patients with and without BRCA1/2 mutations
Sign Up to like & getrecommendations! Published in 2021 at "Breast Cancer Research and Treatment"
DOI: 10.1007/s10549-021-06292-7
Abstract: We evaluated the efficacy and safety of poly-(adenosine diphosphate-ribose) polymerase (PARP) 1 and 2 inhibitor veliparib and temozolomide in metastatic breast cancer patients with and without germline BRCA1/2 mutations. In this single-arm phase II trial,… read more here.
Keywords: breast; breast cancer; metastatic breast; veliparib temozolomide ... See more keywords